Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Issued: 2017-2024

Historic Shares Issued for Aclaris Therapeutics (ACRS) over the last 1 years, with Dec 2024 value amounting to $74.9 million.

  • Aclaris Therapeutics' Shares Issued was N/A to $74.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $45.7 million, marking a year-over-year change of. This contributed to the annual value of $74.9 million for FY2024, which is 180.43% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Shares Issued stood at $74.9 million for Q4 2024, which was up 2.99% from $72.7 million recorded in Q2 2022.
  • In the past 5 years, Aclaris Therapeutics' Shares Issued registered a high of $103.3 million during Q1 2021, and its lowest value of -$101.9 million during Q2 2021.
  • In the last 2 years, Aclaris Therapeutics' Shares Issued had a median value of $72.7 million in 2022 and averaged $49.2 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Shares Issued soared by 413,292.00% in 2021, and later plummeted by 99.96% in 2022.
  • Aclaris Therapeutics' Shares Issued (Quarterly) stood at $25,000 in 2020, then soared by 413,292.00% to -$101.9 million in 2021, then surged by 171.36% to $72.7 million in 2022, then reached $74.9 million in 2024.
  • Its last three reported values are $74.9 million in Q4 2024, $72.7 million for Q2 2022, and $37,000 during Q1 2022.